A-Level Capital

Insilico Medicine, Inc. is a biotechnology company that leverages artificial intelligence (AI) to transform drug discovery, biomarker development, and aging research. Founded in 2014 and based in Baltimore, Maryland, the company has established itself as a pioneer in applying advanced AI techniques, such as generative adversarial networks and reinforcement learning, to create novel molecular structures for various diseases, including cancer and age-related conditions. Insilico Medicine operates an integrated platform that covers all stages of drug discovery, from initial research to clinical trial analysis. Its projects include Pharma.AI, which offers machine learning services to various sectors, and Young.AI, a platform focused on aging predictors. The company also pursues internal drug discovery initiatives targeting diseases like Alzheimer's and Parkinson's, and has partnered with Life Extension to produce nutraceutical products utilizing deep learning and bioinformatics. Additionally, Insilico Medicine provides consumer applications aimed at enhancing health and longevity.

Yet Analytics, Inc. is a data analytics company based in Baltimore, Maryland, founded in 2014. The company operates a comprehensive platform designed to help large organizations collect and analyze data from various sources, including web and mobile applications, wearables, Internet of Things devices, and virtual and augmented reality systems. Yet Analytics offers a modular suite of interoperable software products that cover the entirety of the xAPI learning technology ecosystem, facilitating data inputs, storage, and outputs. Its technology enables businesses to engage with curated learning experiences that align with performance outcomes, providing interactive insights and automated visualizations of trends in learning and team behaviors. By capturing and measuring experience data, Yet Analytics aims to enhance human capital performance and support organizational growth.

Sonavex, Inc. is a medical technology company based in Baltimore, Maryland, founded in 2013. The company specializes in developing innovative imaging solutions, primarily focusing on ultrasound-based methods to detect anastomotic blood clots and assess vascular health. Sonavex's proprietary technology platform provides clinicians with real-time visualization of critical data at the point of care, enabling them to measure intravascular flow metrics and detect post-operative clots effectively. Additionally, the company has developed bioresorbable and echogenic equipment designed to mark at-risk blood vessels, allowing for future assessments of complications. This technology collects essential data, such as volumetric flow rate and vessel morphology, to enhance patient care in surgical settings, ultimately aiming to improve outcomes for surgical patients.